Physiogenex

Translating discovery & preclinical results into predictive clinical validation in the field of metabolic and cardiovascular disorders

Physiogenex is a world leading CRO specializing in preclinical discovery services for biopharmaceutical and nutraceutical companies.

Physiogenex has rapidly achieved global player status by virtue of its unique expertise covering complex metabolic disorders associated with diabetes, obesity, liver diseases, lipid disorders, hypertension and cardiovascular diseases.

Physiogenex pioneers the development of kinetic methods using radioactive labeled tracers and predictive animal nutritional models. We provide our partners with relevant and reliable in vivo preclinical data for successful strategic decision-making.

Physiogenex to present at International Symposium on Atherosclerosis, 30 March - 1 April 2012, Australia.

Dr François Briand will present a poster on “Up-regulation of reverse cholesterol transport requires reduction of apoliprotein-E rich HDL levels in hyperlipidemic hamsters treated with CETP inhibitor torcetrapib.”

Physiogenex obtains the French CIR accreditation

Unique expertise in nutritional and classical animal models
A panel of predictive models merging glucose, lipid and/or lipoprotein disorders due to nutritional imbalances, as observed in human populations

Leader in radioactive tracers and kinetic studies
A holistic approach to assess therapeutic efficacy on key physiological functions, and to screen potential side effects

Innovation and new products

CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveils the results of a new study that supports the potential of CETP inhibitors to prevent cardiovascular risk like dyslipidemia, a major characteristic of type 2 diabetic patients.

A new study demonstrates that the CETP inhibitor anacetrapib promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.

Using independent approaches to assess cholesterol metabolism (macrophage-to-feces reverse cholesterol transport, HDL-cholesteryl esters kinetics and measurement of bulk cholesterol and bile acids in feces), this study supports the development of the CETP inhibitor anacetrapib as a novel lipid therapy for the treatment of dyslipidemia and atherosclerosis.

All news

Metabolic disorder diabetes